Ilsung Pharmaceuticals Co., Ltd. (003120.KS)
KRW 15970.0
(-0.19%)
KRW 15970.0
(-0.19%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 419.18 Billion KRW | -15.22% |
| 2022 | 494.42 Billion KRW | 33.13% |
| 2021 | 371.38 Billion KRW | 0.04% |
| 2020 | 371.22 Billion KRW | 0.46% |
| 2019 | 369.51 Billion KRW | 6.41% |
| 2018 | 347.26 Billion KRW | -0.06% |
| 2017 | 347.46 Billion KRW | 2.65% |
| 2016 | 338.5 Billion KRW | -7.77% |
| 2015 | 367.02 Billion KRW | -3.0% |
| 2014 | 378.37 Billion KRW | 1.53% |
| 2013 | 372.65 Billion KRW | -2.86% |
| 2012 | 383.62 Billion KRW | -7.16% |
| 2011 | 413.19 Billion KRW | -11.98% |
| 2010 | 469.4 Billion KRW | 27.79% |
| 2009 | 367.32 Billion KRW | 27.58% |
| 2008 | 287.91 Billion KRW | -41.73% |
| 2007 | 494.08 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 403.86 Billion KRW | -3.19% |
| 2024 Q1 | 417.16 Billion KRW | -0.48% |
| 2023 Q4 | 419.18 Billion KRW | -7.73% |
| 2023 Q1 | 498.85 Billion KRW | 0.9% |
| 2023 FY | 419.18 Billion KRW | -15.22% |
| 2023 Q3 | 454.3 Billion KRW | 0.75% |
| 2023 Q2 | 450.91 Billion KRW | -9.61% |
| 2022 Q2 | 487.2 Billion KRW | 31.65% |
| 2022 Q1 | 370.07 Billion KRW | -0.35% |
| 2022 FY | 494.42 Billion KRW | 33.13% |
| 2022 Q4 | 494.42 Billion KRW | -0.05% |
| 2022 Q3 | 494.64 Billion KRW | 1.53% |
| 2021 Q2 | 367.94 Billion KRW | 0.12% |
| 2021 FY | 371.38 Billion KRW | 0.04% |
| 2021 Q4 | 371.38 Billion KRW | 1.03% |
| 2021 Q1 | 367.48 Billion KRW | -1.01% |
| 2021 Q3 | 367.59 Billion KRW | -0.1% |
| 2020 Q2 | 368.92 Billion KRW | -0.25% |
| 2020 Q1 | 369.86 Billion KRW | 0.09% |
| 2020 Q3 | 366.91 Billion KRW | -0.55% |
| 2020 FY | 371.22 Billion KRW | 0.46% |
| 2020 Q4 | 371.22 Billion KRW | 1.18% |
| 2019 Q2 | 351.11 Billion KRW | 0.4% |
| 2019 Q4 | 369.51 Billion KRW | 4.94% |
| 2019 FY | 369.51 Billion KRW | 6.41% |
| 2019 Q1 | 349.73 Billion KRW | 0.71% |
| 2019 Q3 | 352.1 Billion KRW | 0.28% |
| 2018 FY | 347.26 Billion KRW | -0.06% |
| 2018 Q2 | 347.47 Billion KRW | -0.38% |
| 2018 Q4 | 347.26 Billion KRW | -0.02% |
| 2018 Q1 | 348.79 Billion KRW | 0.38% |
| 2018 Q3 | 347.34 Billion KRW | -0.04% |
| 2017 Q3 | 347.26 Billion KRW | 0.81% |
| 2017 Q1 | 345.23 Billion KRW | 1.99% |
| 2017 FY | 347.46 Billion KRW | 2.65% |
| 2017 Q4 | 347.46 Billion KRW | 0.06% |
| 2017 Q2 | 344.48 Billion KRW | -0.22% |
| 2016 Q3 | 340.25 Billion KRW | 0.42% |
| 2016 FY | 338.5 Billion KRW | -7.77% |
| 2016 Q4 | 338.5 Billion KRW | -0.52% |
| 2016 Q2 | 338.83 Billion KRW | -4.65% |
| 2016 Q1 | 355.36 Billion KRW | -3.18% |
| 2015 Q2 | 396.72 Billion KRW | 5.13% |
| 2015 Q3 | 368.96 Billion KRW | -7.0% |
| 2015 Q4 | 367.02 Billion KRW | -0.52% |
| 2015 FY | 367.02 Billion KRW | -3.0% |
| 2015 Q1 | 377.36 Billion KRW | -0.27% |
| 2014 Q3 | 423.33 Billion KRW | 0.46% |
| 2014 Q2 | 421.41 Billion KRW | 11.2% |
| 2014 FY | 378.37 Billion KRW | 1.53% |
| 2014 Q4 | 378.37 Billion KRW | -10.62% |
| 2014 Q1 | 378.97 Billion KRW | 1.7% |
| 2013 Q3 | 378.76 Billion KRW | 7.37% |
| 2013 Q4 | 372.65 Billion KRW | -1.61% |
| 2013 FY | 372.65 Billion KRW | -2.86% |
| 2013 Q1 | 412.66 Billion KRW | 7.57% |
| 2013 Q2 | 352.77 Billion KRW | -14.51% |
| 2012 Q4 | 383.62 Billion KRW | -4.13% |
| 2012 Q3 | 400.15 Billion KRW | -0.74% |
| 2012 Q2 | 403.13 Billion KRW | -14.19% |
| 2012 FY | 383.62 Billion KRW | -7.16% |
| 2012 Q1 | 469.82 Billion KRW | 13.71% |
| 2011 Q3 | 425.75 Billion KRW | -12.75% |
| 2011 Q1 | 441.2 Billion KRW | -6.01% |
| 2011 Q2 | 487.95 Billion KRW | 10.6% |
| 2011 FY | 413.19 Billion KRW | -11.98% |
| 2011 Q4 | 413.19 Billion KRW | -2.95% |
| 2010 Q2 | 348.08 Billion KRW | -10.96% |
| 2010 Q1 | 390.94 Billion KRW | 6.43% |
| 2010 Q4 | 469.4 Billion KRW | 20.48% |
| 2010 Q3 | 389.6 Billion KRW | 11.93% |
| 2010 FY | 469.4 Billion KRW | 27.79% |
| 2009 Q4 | 367.32 Billion KRW | 4.19% |
| 2009 Q3 | 352.56 Billion KRW | 16.98% |
| 2009 Q2 | 301.4 Billion KRW | 2.62% |
| 2009 Q1 | 293.71 Billion KRW | 2.01% |
| 2009 FY | 367.32 Billion KRW | 27.58% |
| 2008 Q1 | 498.01 Billion KRW | 0.79% |
| 2008 Q2 | 412.58 Billion KRW | -17.15% |
| 2008 FY | 287.91 Billion KRW | -41.73% |
| 2008 Q3 | 376.55 Billion KRW | -8.73% |
| 2008 Q4 | 287.91 Billion KRW | -23.54% |
| 2007 Q2 | 355.23 Billion KRW | 18.99% |
| 2007 Q3 | 468.82 Billion KRW | 31.98% |
| 2007 FY | 494.08 Billion KRW | 0.0% |
| 2007 Q4 | 494.08 Billion KRW | 5.39% |
| 2007 Q1 | 298.54 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -111.484% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 78.581% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 52.202% |
| HANDOK Inc. | 790.33 Billion KRW | 46.961% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -145.686% |
| Yuhan Corporation | 2814.07 Billion KRW | 85.104% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 68.128% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -348.432% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 78.525% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -74.847% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 10.602% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -264.598% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -77.211% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -20.323% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -111.484% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 16.124% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 28.878% |
| JW Holdings Corporation | 1176.26 Billion KRW | 64.363% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 31.422% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 70.11% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 35.013% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -19.74% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -172.129% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -13.087% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 13.982% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -111.484% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 61.116% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 76.321% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 35.013% |
| Yuhan Corporation | 2814.07 Billion KRW | 85.104% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 52.365% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -84.99% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 57.817% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 35.013% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 0.169% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 10.594% |
| CKD Bio Corp. | 293.78 Billion KRW | -42.686% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 17.482% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 25.803% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -4.477% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -19.74% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 71.21% |
| Boryung Corporation | 922.36 Billion KRW | 54.553% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 5.26% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 10.602% |
| JW Lifescience Corporation | 255.83 Billion KRW | -63.851% |